Loading...
XKRX
017180
Market cap39mUSD
Dec 05, Last price  
1,756.00KRW
1D
2.99%
1Q
0.17%
Jan 2017
-65.73%
IPO
-34.69%
Name

Myungmoon Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:017180 chart
P/E
P/S
0.31
EPS
Div Yield, %
Shrs. gr., 5y
5.99%
Rev. gr., 5y
4.54%
Revenues
186.44b
+9.95%
60,927,940,00077,390,430,00097,191,219,000105,183,289,000125,619,902,280100,538,968,880103,723,479,410105,420,701,980125,100,920,170142,179,739,050140,137,942,910147,498,532,160149,346,276,620127,852,855,900137,759,902,000152,134,940,500169,567,372,990186,443,052,000
Net income
-3.03b
L-32.94%
6,583,195,0004,863,329,0002,940,981,0003,067,853,0004,554,000,000-12,273,359,0001,025,971,000761,490,080-16,135,460,8406,745,899,0007,807,498,230988,268,550-20,832,841,850-27,753,013,560-6,804,256,8007,867,987,000-4,524,837,000-3,034,504,000
CFO
-1.34b
L-74.18%
459,089,000-1,718,672,000-4,220,097,0002,870,640,000-1,415,963,4402,780,662,8102,003,532,500-36,233,890-5,504,596,3805,601,082,0508,023,816,12011,407,275,730-2,941,626,920-16,672,465,190854,995,9505,474,842,480-5,180,519,690-1,337,700,000
Dividend
Dec 27, 201795.424133 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, fillers, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, oral disease products, antidiarrheal agents, digestive system products, cold drugs, calcium products, nasal sprays, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.
IPO date
Jul 10, 2008
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT